Bank of New York Mellon Corp Boosts Stake in Bio-Rad Laboratories, Inc. (BIO)

Bank of New York Mellon Corp grew its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 17.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 270,927 shares of the medical research company’s stock after acquiring an additional 39,571 shares during the quarter. Bank of New York Mellon Corp owned 0.90% of Bio-Rad Laboratories worth $62,915,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of BIO. Hosking Partners LLP lifted its holdings in shares of Bio-Rad Laboratories by 4.2% during the fourth quarter. Hosking Partners LLP now owns 100,854 shares of the medical research company’s stock valued at $23,420,000 after acquiring an additional 4,041 shares during the period. BlackRock Inc. lifted its holdings in shares of Bio-Rad Laboratories by 3.6% during the fourth quarter. BlackRock Inc. now owns 1,936,008 shares of the medical research company’s stock valued at $449,580,000 after acquiring an additional 68,124 shares during the period. Westfield Capital Management Co. LP lifted its holdings in shares of Bio-Rad Laboratories by 8.4% during the fourth quarter. Westfield Capital Management Co. LP now owns 376,018 shares of the medical research company’s stock valued at $87,319,000 after acquiring an additional 29,265 shares during the period. California Public Employees Retirement System lifted its holdings in shares of Bio-Rad Laboratories by 3.1% during the fourth quarter. California Public Employees Retirement System now owns 55,110 shares of the medical research company’s stock valued at $12,798,000 after acquiring an additional 1,649 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Bio-Rad Laboratories by 2.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 8,458 shares of the medical research company’s stock valued at $1,964,000 after acquiring an additional 163 shares during the period. 63.00% of the stock is owned by institutional investors.

A number of research analysts have issued reports on BIO shares. Zacks Investment Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Thursday, January 3rd. Barclays lifted their price objective on Bio-Rad Laboratories from $315.00 to $340.00 and gave the company an “overweight” rating in a report on Friday, March 1st. Finally, Deutsche Bank lifted their price objective on Bio-Rad Laboratories from $330.00 to $350.00 and gave the company a “buy” rating in a report on Friday, March 1st. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $349.29.

Shares of NYSE:BIO opened at $310.33 on Friday. Bio-Rad Laboratories, Inc. has a twelve month low of $220.05 and a twelve month high of $345.15. The firm has a market capitalization of $9.30 billion, a PE ratio of 53.14, a price-to-earnings-growth ratio of 2.88 and a beta of 1.25. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.51 and a quick ratio of 3.20.

ILLEGAL ACTIVITY NOTICE: “Bank of New York Mellon Corp Boosts Stake in Bio-Rad Laboratories, Inc. (BIO)” was originally reported by PressOracle and is the sole property of of PressOracle. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://pressoracle.com/news/2019/03/17/bank-of-new-york-mellon-corp-boosts-stake-in-bio-rad-laboratories-inc-bio.html.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Featured Story: How is inflation measured?

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bio-Rad Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter.